Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/20/2/393/395333/mdn729.pdf
Reference4 articles.
1. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
2. Association of diastolic blood pressure ≥ 90 mmHg with overall survival in patients treated with axitinib;Rini;J Clin Oncol,2008
3. Hypertension as a predictive factor of sunitinib activity;Rixe;Ann Oncol,2007
4. Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine;Friberg;J Clin Oncol,2005
Cited by 108 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer;International Journal of Clinical Oncology;2023-06-15
2. Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment;Global Health & Medicine;2021-08-31
3. Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer ( SCC ): A post hoc analysis of the ALTER0303 trial;Thoracic Cancer;2021-07-17
4. Vascular endothelial growth factor inhibitor induced hypertension: Retrospective analysis of the impact of blood pressure elevations on outcomes;Journal of Oncology Pharmacy Practice;2021-01-11
5. Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events;Urologic Oncology: Seminars and Original Investigations;2020-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3